Central vision loss a problem following trabeculectomy?

Article

In patients with advanced visual field loss undergoing trabeculectomy with mitomycin C, there is a risk of severe loss of central vision.

In patients with advanced visual field loss undergoing trabeculectomy with mitomycin C, there is a risk of severe loss of central vision, according to the results of a study published in the August issue of Archives of Ophthalmology.

A retrospective review was conducted of the records of patients with severe preoperative visual field defects undergoing trabeculectomy between June 1998 and October 2005. Severe loss of central vision was defined as visual acuity (VA) of 20/200 or less in the affected eye, counting fingers or less if preoperative VA was less than 20/200, or a greater than four line reduction in Snellen VA.

Of 117 subjects, central vision loss occurred in seven (6%), due to hypotony maculopathy (three cases), uncontrolled elevated intraocular pressure (IOP) (two cases), posterior subcapsular cataract increase (one case) and inflammatory reaction (one case). A significant reduction in VA was noted following surgery, from -0.31 to -0.39 (logMAR, p=0.01). The patients who did suffer a severe loss of central vision, had significantly higher mean ±SD preoperative IOPs and higher rates of surgical complications compared with those who did not.

It would seem that there is a risk of severe central vision loss after trabeculectomy in patients with advanced visual field loss.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.